SCHEMBL340408

SCHEMBL340408

CCCC(=O)C(Cc1ccc(-c2ccccc2)cc1)(C(=O)O)C(=O)ON

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
HPGD P15428 1/20 0.43
SRR Q9GZT4 2/20 0.40
PSAT1 Q9Y617 2/20 0.40
FFAR1 O14842 2/20 0.39
IDO1 P14902 2/20 0.37
AGXT P21549 2/20 0.37
ABCC4 O15439 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
PTGS1 P23219 1/20 0.37
HTT P42858 1/20 0.37
HIF1A Q16665 1/20 0.36
MAPT P10636 1/20 0.36
MMP12 P39900 1/20 0.35
SLC13A5 Q86YT5 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL340185 0.91 SRR (0.40) SMN1; SMN2L3MBTL1SRRPSAT1FFAR1
SCHEMBL27810707 0.74 ALDH1A1 (0.40) SRRPSAT1LMNAMAPTSLC13A5
SCHEMBL1439605 0.73 ALDH1A1 (0.52) SMN1; SMN2L3MBTL1HPGDFFAR1ABCC4
SCHEMBL369881 0.70 PLA2G10 (0.38) LMNAGSK3B
SCHEMBL340407 0.69 L3MBTL1 (0.46) SMN1; SMN2L3MBTL1HPGDFFAR1MMP12
SCHEMBL27797467 0.68 ARG1 (0.50) SMN1; SMN2L3MBTL1HPGDSRRPSAT1
SCHEMBL14037306 0.67 BLM (0.69) SMN1; SMN2HPGDFFAR1ABCC4LMNA
SCHEMBL6532058 0.67 BLM (0.69) SMN1; SMN2HPGDFFAR1ABCC4LMNA
SCHEMBL7904968 0.67 SMN1; SMN2 (0.78) SMN1; SMN2HPGDSRRPSAT1FFAR1
SCHEMBL20661665 0.67 ABCC4 (0.52) SMN1; SMN2L3MBTL1HPGDFFAR1ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181175-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2015-11-10 US disclosed
EP-2387558-B1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2014-08-27 EP disclosed
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2014-06-26 US disclosed
US-8703990-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2014-04-22 US disclosed
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID NOVARTIS AG (CH) 2012-01-19 US disclosed
EP-2387558-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2011-11-23 EP disclosed
US-20110253230-A1 Temperature Sensitive Valve Having Shape Memory Actuator OMNITEK PARTNERS LLC (US) 2011-10-20 US disclosed
WO-2010081410-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 SMN1; SMN2 3020/4885L3MBTL1 3543/4885HPGD 782/4885
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 SMN1; SMN2 3020/4885L3MBTL1 3543/4885HPGD 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.